Diranersen
| Clinical data | |
|---|---|
| Other names | BIIB-080; BIIB080; IONIS-MAPTRx; ISIS-814907 |
| Routes of administration | Intrathecal injection[1] |
| Drug class | Antisense oligonucleotide against tau |
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| UNII | |
Diranersen (INN; developmental code names BIIB080, IONIS-MAPTRx, and ISIS-814907) is an antisense oligonucleotide (ASO) against tau which is under development for the treatment of Alzheimer's disease.[1][2][3][4] It is given by intrathecal injection.[1] The drug is under development by Ionis Pharmaceuticals and Biogen.[1][2][3] As of July 2026, it is in phase 2 clinical trials for Alzheimer's disease.[1][2][3] Diranersen has been found to decrease levels of tau in cerebrospinal fluid by 30 to 65%[3][4] and was reported to slightly slow cognitive decline, by 26%, in a preliminary phase 2 trial.[4][5] This degree of slowing is on par with that of existing anti-amyloid antibodies.[5] The drug is one of the most clinically advanced anti-tau drugs under development.[6]
See also
[edit]References
[edit]- 1 2 3 4 5 "Diranersen". AdisInsight. 2 July 2026. Retrieved 19 July 2026.
- 1 2 3 "Delving into the Latest Updates on ISIS-814907 with Synapse". Synapse. 20 June 2026. Retrieved 19 July 2026.
- 1 2 3 4 "Diranersen". ALZFORUM. 14 May 2026. Retrieved 19 July 2026.
- 1 2 3 Mackenzie RJ (14 July 2026). "A new sort of Alzheimer's drug shows glimmers of promise". Science News. Retrieved 19 July 2026.
- 1 2 Joseph A (14 July 2026). "Biogen Alzheimer's drug slowed decline at rates on par with approved therapies, study shows". STAT. Retrieved 19 July 2026.
- ↑ Incorvaia D (14 July 2026). "Biogen defends anti-tau drug after stock slides on Alzheimer's readout". Fierce Biotech. Retrieved 19 July 2026.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information. |